Search
Search Results
-
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
BackgroundRC48-antibody-drug conjugates (ADC) link humanized anti-HER2 immunoglobulin with monomethyl auristatin E (MMAE). Clinical trials suggest...
-
Diagnostic Performances of ADC Value in Diffusion-Weighted MR Imaging for Differential Diagnosis of Breast Lesions in 1.5 T: A Systematic Review and Meta-analysis
PurposeMedical technology has gone a long way in diagnosis and characterization of breast tumors. Diffusion-weighted MR imaging is the state of the...
-
Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma
PurposeThe aim of this prospective study was to investigate the prognostic value of metabolic tumor volume (MTV) and apparent diffusion coefficient...
-
ADC textural features in patients with single brain metastases improve clinical risk models
AimsIn this retrospective study we performed a quantitative textural analysis of apparant diffusion coefficient (ADC) images derived from diffusion...
-
Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma
Antibody drug conjugates (ADC) are a new class of agents that have been expanding the spectrum of treatment options in metastatic urothelial...
-
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors
BackgroundHER3 (ErbB3), a member of the human epidermal growth factor receptor family, is frequently overexpressed in various cancers. Multiple...
-
MRI-based radiomics and ADC values are related to recurrence of endometrial carcinoma: a preliminary analysis
BackgroundTo identify predictive value of apparent diffusion coefficient (ADC) values and magnetic resonance imaging (MRI)-based radiomics for all...
-
Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy
BackgroundThe immunohistochemical test (IHC) of HER2 and HR can provide prognostic information and treatment guidance for invasive breast cancer...
-
AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage
The receptor tyrosine kinase AXL is an emerging driver of cancer recurrence, while its molecular mechanism remains unclear. In this study we...
-
-
Improving Predictive Ability of Prostate Cancer Aggressiveness Using Multi-Modal Radiomic Features and Feature-Level Correlations in Multi-parametric MRI
PurposeThis study aims to improve the predictive ability of prostate cancer aggressiveness by leveraging complementary information from various...
-
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
BackgroundAdvanced colorectal cancer (CRC) is difficult to treat. For that reason, the development of novel therapeutics is necessary. Here we...
-
Assessing the radiofrequency shielding effect of titanium mesh on diffusion-weighted imaging: a comparative study of the twice-refocused spin–echo and Stejskal–Tanner sequences
This study compared twice-refocused spin–echo sequence (TRSE) and Stejskal–Tanner sequence (ST) to evaluate their respective effects on the image...
-
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
High-grade serous ovarian cancer (HGSOC) and ovarian clear cell carcinoma (CC), are biologically aggressive tumors endowed with the ability to...
-
Assessing ADC Plasma Stability by LC-MS Methods
Plasma stability of ADCs can have a profound impact on ADC efficacy and safety. LC-MS methods enable the detection and characterization of ADC to...
-
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
A next generation multiscale quantitative systems pharmacology (QSP) model for antibody drug conjugates (ADCs) is presented, for preclinical to...
-
The target atlas for antibody-drug conjugates across solid cancers
Antibody-Drug Conjugates (ADCs) represent a rapidly advancing category of oncology therapeutics, spanning the targeted therapy for both hematologic...
-
Apparent diffusion coefficient values predict response to brachytherapy in bulky cervical cancer
BackgroundDiffusion-weighted magnetic resonance imaging (DWI) provides a measurement of tumor cellularity. We evaluated the potential of apparent...
-
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
Antibody drug conjugate (ADC) therapy has become one of the most promising approaches in cancer immunotherapy. Bispecific targeting could enhance the...
